Status:
RECRUITING
Topical Insulin for Glaucoma
Lead Sponsor:
Stanford University
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this Phase 1 trial is to determine the safety over 1-2 months of topic sterile human recombinant insulin on subjects with optic neuropathies (glaucoma, ischecmic optic neuropathy, and o...
Eligibility Criteria
Inclusion
- Capable to provide informed consent
- Diagnosis of optic neuropathy either glaucoma or NAION or optic disc drusen.
- Only one eye per patient will be selected as the study eye - if both eyes meet the inclusion criteria, the eye with the worse acuity and /or visual field will be selected. The contralateral eye will be left untouched.
Exclusion
- Pregnant or breastfeeding woman
- Presence of any ocular pathologies other than glaucoma that contributes to the severe vision loss (retinopathy / maculopathy, severe uveitis, keratopathy, etc.)
- Diagnosis of glucose intolerance, type 1 or 2 diabetes mellitus
- Inability to perform reliable visual field
- Unable to provide informed consent
- Unable to complete the tests and follow-ups required by the study
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT05206877
Start Date
April 1 2022
End Date
December 31 2026
Last Update
November 25 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Byers Eye Institute at Stanford University
Palo Alto, California, United States, 94303